Xeris Biopharma Holdings, Inc. announced it has entered into an amended and restated senior secured term loan agreement (?debt facility?) with funds managed by Hayfin Capital Management LLP (?Hayfin?) to provide Xeris $200.0 million of capital at close and the ability to draw down another $15.2 million to redeem Xeris? outstanding 5.00% convertible senior notes due 2025. Under the terms of the new debt facility, Xeris drew down $200.0 million on the closing date to repay its existing term loan of $150.0 million with Hayfin, plus associated interest and fees, which resulted in an increase of approximately $35 million to Xeris?

cash balance. Net proceeds are for working capital and general corporate purposes. An additional $15.2 million of the debt facility is available to redeem, if needed, Xeris?

outstanding 5.00% convertible senior notes due mid-2025. The maturity of the debt facility is five (5) years from the closing date. Amounts borrowed under the debt facility bear interest at an annual rate equal to 6.95% plus the greater of (i) CME Term SOFR, and (ii) 2.00% per annum.

Xeris is entitled to make interest-only payments on a quarterly basis until the maturity date or earlier prepayment of the loan. During the term of the loan, Xeris is required to maintain certain minimum liquidity and revenue requirements.